Loading stock data…
$4.68-0.10 (-2.09%)
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity.
Corbus Pharmaceuticals Holdings, Inc. in the Healthcare sector is trading at $4.68 with a market capitalization of $195M. Wall Street consensus targets $34.02 (10 analysts), implying a +627.0% move over the next 12 months. The stock is currently near its 52-week low of $4.62, remaining 47.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 9 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$36.19M↓ | -$24.30M↓ | -$21.97M↑ | -$24.42M↓ | -$19.15M |
| Net Income | -$35.04M↓ | -$22.97M↓ | -$20.55M↑ | -$23.34M↓ | -$17.66M |
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to rel...